SLC29A2 and cancer: In support of this idea, fluorescent immunostaining (Fig. 6C) and DNA dot blot analysis (Supplementary Fig. 6) revealed that FTD incorporation into nuclear DNA in human cancer cell lines was effectively blocked by the nucleoside transporter inhibitor dipyridamole (DPM), which inhibits both hENT1 and hENT2 activity22.